核酸适配体技术及其在肿瘤诊断和治疗中的应用

核酸适配体是一类通过指数富集的配体系统进化（SELEX）技术获得的具有独特三维构象的小分子RNA 或单链DNA。核酸适 配体能高亲和力和高特异性与靶点结合,同时具有自身分子质量小、免疫原性低、热/化学稳定性高、靶标分子范围广等特点,广泛应用 于疾病诊断、治疗、生物传感器、生物标志物筛选、新药研发等领域。综述近年来核酸适配体在肿瘤诊断和治疗方面的应用,并对核酸 适配体的临床研究现状、市场前景及面临挑战和发展趋势作简要分析。     

analytica China 2014:看新兴医疗诊断技术助力健康产业发展

<正>随着生化、免疫等诊断技术的不断完善,市场逐渐走向饱和,但体外诊断市场却仍显示出巨大的潜力。据权威机构FS(FrostSullivan)咨询预测,2012~2014年,全球体外诊断市场的年复合增长率将达6.58%。在我国,医疗器械上市企业中70%是做诊断类的产品。随着我国"高端医     

analytica China2014:新兴医疗诊断技术促进健康产业发展

<正>随着生化、免疫等诊断技术的不断完善,市场逐渐走向饱和,但体外诊断市场却仍显示出巨大的潜力。据FS咨询机构(FrostSullivan)预测,2012~2014年全球体外诊断市场的年度复合增长率将达6.58%,在我国的医疗器械上市企业中,70%是做诊断类的产品。随着我国"高端医疗诊断设备发展专项计划"启动和医疗改革的不断深入,以及医疗需求的不断增长,我国医疗器械行业发展形势一片大好。在即将举办的慕尼黑上海分析生化展(analytica China)上,汇聚了全球众多医疗及生物技术的知名企业品牌,包括Agilent、Thermo Fisher Scientific、GE     

基于流技术的医学影像系统的研究

本文围绕医学影像数据实时浏览这一问题,首先分析了流技术、渐进技术和JPEG2000标准这几种技术在医疗领域内的作用。以及存在的一些问题。根据医学信息和医学影像的特性,提出了并行结构与层次设计的构想,针对不同网络条件下。阐述了流技术框架下的医学影像系统总体设计的思路和模型。通过临床应用和测试结果。在实践中验证了设计思想的可行性与优越性。     

基于专利分析的医学科技重点技术前沿领域的识别研究

目的:采用定量分析与定性分析相结合的方法识别医学科技重点技术前沿领域。方法:在Thomson Innovation数据库中检索2006-2012年制药技术、生物医药技术和医疗器械三个领域申请的专利数量,采用专利计量分析、统计学趋势分析等定量分析方法结合专家专业知识的定性分析方法对检索、采集的专利进行分析并识别前沿领域。前沿领域的选择原则是专利申请数量标化平均值较高(制药技术、生物医药技术和医疗器械领域标化平均值分别选择大于10%、15%和20%的子领域),或者有显著性增长趋势(P0.05且b0)。结果:本研究共识别医学科技重点技术前沿领域12个,其中制药技术前沿领域4个,分别是:天然产物,普通药,杂环化合物和其他有机物;生物医药技术前沿领域4个,分别是:疾病诊断和检测,基因治疗和核苷类药物,蛋白多肽类药物和生物合成技术;医疗器械前沿领域4个,分别是:电子医疗设备,诊断及手术设备,消毒、注射及电疗设备和医疗救助及口服设备。结论:通过定量与定性分析方法相结合共识别医学科技重点技术前沿领域12个,对专利进行多角度分析可以全面把握前沿领域的技术发展方向和特点,为我国医学科技政策的制定提供基于数据和事实的信息支撑。     

2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients

In view of the increasing complexity of both cardiovascular implantable electronic devices (CIEDs) and patients in the current era, practice guidelines, by necessity, have become increasingly specific. This document is an expert consensus statement that has been developed to update and further delineate indications and management of CIEDs in pediatric patients, defined as ≤21 years of age, and is intended to focus primarily on the indications for CIEDs in the setting of specific disease categories. The document also highlights variations between previously published adult and pediatric CIED recommendations and provides rationale for underlying important differences. The document addresses some of the deterrents to CIED access in low- and middle-income countries and strategies to circumvent them. The document sections were divided up and drafted by the writing committee members according to their expertise. The recommendations represent the consensus opinion of the entire writing committee, graded by class of recommendation and level of evidence. Several questions addressed in this document either do not lend themselves to clinical trials or are rare disease entities, and in these instances recommendations are based on consensus expert opinion. Furthermore, specific recommendations, even when supported by substantial data, do not replace the need for clinical judgment and patient-specific decision-making. The recommendations were opened for public comment to Pediatric and Congenital Electrophysiology Society (PACES) members and underwent external review by the scientific and clinical document committee of the Heart Rhythm Society (HRS), the science advisory and coordinating committee of the American Heart Association (AHA), the American College of Cardiology (ACC), and the Association for European Paediatric and Congenital Cardiology (AEPC). The document received endorsement by all the collaborators and the Asia Pacific Heart Rhythm Society (APHRS), the Indian Heart Rhythm Society (IHRS), and the Latin American Heart Rhythm Society (LAHRS). This document is expected to provide support for clinicians and patients to allow for appropriate CIED use, appropriate CIED management, and appropriate CIED follow-up in pediatric patients.